OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
June 25, 2020
Full results from the Phase III ETHOS trial have demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations in patients with moderate to very severe COPD after treatment with triple-combination therapy Breztri Aerosphere.
Biotechnology company, ILC Therapeutics, has revealed that it has entered into a research partnership with the University of St Andrews aimed at progressing a therapeutic drug that can treat COVID-19 to clinical trials.
June 23, 2020
The agency will be waiving fees for scientific advice for academia developing orphan drugs.
June 12, 2020
Leo Pharma, medical dermatology specialist, has announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for tralokinumab.
The Biomedical Catalyst has been relaunched, meaning that innovative biotech companies will have the opportunity to access a share of £30 million (US$38 million) in grant funding.
June 11, 2020
The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.
June 05, 2020
The collaboration will focus on novel therapeutics targeting RNA-modifying proteins for cancer treatment.
June 02, 2020
Achieving herd immunity will require testing, data, a vaccine, and public support.
The correct mix of excipients is crucial to the success of fast dissolving/orally disintegrating dosage forms.
Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts.